GLP-1 Agonists (Ozempic/Semaglutide) for Longevity and Anti-Aging: 2026 Update
Drugs like Ozempic (semaglutide for diabetes), Wegovy (higher-dose semaglutide for weight loss), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight loss) mimic the gut hormone GLP-1, promoting fullness, slowing digestion, and enhancing insulin sensitivity. In 2025, these therapies have solidified their role not just in obesity management but also in cardiovascular and kidney protection, with the World Health Organization issuing global guidelines endorsing their use for obesity as a chronic disease. Credit: GoodRx Health Key Benefits in 2025 GLP-1 agonists continue to outperform expectations: Significant Weight Loss : Clinical trials show 15-21% average body weight reduction over 68-72 weeks (e.g., Wegovy ~15%, Zepbound ~21%). Dual agonists like tirzepatide (Mounjaro/Zepbound) often edge out single GLP-1 agents like semaglutide. Blood Sugar Control : Superior glycemic management for type 2 diabetes, reducing HbA1c by up to 2.4%. Cardiovascular Protection : Ro...